Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enfortumab vedotin - Astellas Pharma/Seagen

X
Drug Profile

Enfortumab vedotin - Astellas Pharma/Seagen

Alternative Names: AGS-22C3; AGS-22CE; AGS-22M6E; AGS-22ME; AGS-M6; ASG-22CE; ASG-22M6E; ASG-22ME; Enfortumab; Enfortumab vedotin; Enfortumab vedotin-ejfv; PADCEV

Latest Information Update: 01 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agensys; Seattle Genetics
  • Developer Astellas Pharma; Astellas Pharma Global Development; Merck & Co; Seagen; Utah State University
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Urogenital cancer
  • Phase III Bladder cancer
  • Phase II Prostate cancer; Solid tumours

Most Recent Events

  • 28 Mar 2024 Preregistration for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (IV)
  • 15 Feb 2024 Enfortumab vedotin receives priority review status for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Japan
  • 31 Jan 2024 Preregistration for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Japan (IV) in January 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top